Avantor (AVTR) Q2 FY26 earnings call

Avantor's Q2 FY26 results exceeded expectations, primarily driven by the VWR segment's earlier-than-anticipated return to 1.7% organic growth, fueled by strategic actions and digital enhancements. The Bioscience & Medtech Products (BMP) segment, while down organically, showed strong order intake and is poised for a second-half recovery. The company raised its full-year organic revenue and adjusted EPS guidance, reflecting improved performance and confidence in its "Revival" program, which focuses on operational excellence and debt reduction.